Edouard Leroy joins as Chief Business Development Officer
We are pleased to announce a strategic addition to Mablink’s team with the arrival of Edouard Leroy as our Chief Business Development Officer.
Newsroom
Mablink will attend MEET2WIN in Bordeaux (6-7 May, 2020)
Mablink will take the opportunity to meet with pharmaceutical companies and investors during MEET2WIN, the European oncology partnering convention entirely dedicated to open innovation, collaborative research and technology transfer. Two vibrant days dedicated to oncology and innovation.
Mablink will give a lecture at Montreal University (27 February, 2020)
Mablink Bioscience will present the latest technological advances of its ADC platform for highly-loaded & highly hydrophilic ADCs
Mablink will be attending the World ADC congress in London (2-5 March, 2020)
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.
Mablink adopts Agatha Software solutions
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
Come and meet us at BioFIT on December 10 and 11, 2019 in Marseille!
Discover Mablink’s ADC platform and meet our COO Valérie Attuil-Audenis and our CEO Jean-Guillaume Lafay at BioFIT Event on December 10 and 11 in Marseille
Mablink is an awardee of the CLARA Proof of Concept Program 2019
Mablink receives the support of the Canceropole CLARA to push forward the development of its ADC platform
Mablink receives iLab 2019 Award
Mablink receives the iLab 2019 award in the presence of French Minister of Higher Education, Research and Innovation, Mrs Frédérique Vidal, and Bpifrance, at the innovation awards ceremony in Paris.
Mablink in the French « Journal des Entreprises »
Photo by P. Thiessen Mablink is flying high! The French Journal des Entreprises relates in a recent article Mablink’s last fundraisings with the coming of a new investor for 125k€, …
Mablink is incubated and supported by PULSALYS
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.